Wall Street analysts expect Exelixis, Inc. (NASDAQ:EXEL – Get Rating) to announce $0.12 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Exelixis’ earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.15. The company is scheduled to report its next earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Exelixis will report full year earnings of $0.85 per share for the current year, with EPS estimates ranging from $0.68 to $0.94. For the next financial year, analysts expect that the firm will report earnings of $1.12 per share, with EPS estimates ranging from $0.65 to $1.46. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Exelixis.
Exelixis (NASDAQ:EXEL – Get Rating) last issued its quarterly earnings results on Thursday, February 17th. The biotechnology company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.22. The company had revenue of $451.14 million during the quarter, compared to analyst estimates of $357.17 million. Exelixis had a return on equity of 11.17% and a net margin of 16.10%.
In other Exelixis news, Director Stelios Papadopoulos sold 84,515 shares of the stock in a transaction on Tuesday, February 22nd. The stock was sold at an average price of $19.56, for a total value of $1,653,113.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Alan M. Garber sold 21,301 shares of the business’s stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $21.00, for a total value of $447,321.00. The disclosure for this sale can be found here. Insiders sold a total of 205,229 shares of company stock valued at $4,017,116 in the last 90 days. Corporate insiders own 3.30% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC lifted its stake in shares of Exelixis by 9.8% in the 1st quarter. CWM LLC now owns 5,137 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 460 shares during the period. Arizona State Retirement System lifted its stake in Exelixis by 0.7% in the third quarter. Arizona State Retirement System now owns 85,364 shares of the biotechnology company’s stock valued at $1,805,000 after buying an additional 557 shares during the period. Pitcairn Co. boosted its holdings in Exelixis by 6.0% during the third quarter. Pitcairn Co. now owns 11,584 shares of the biotechnology company’s stock worth $245,000 after buying an additional 659 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Exelixis by 3.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 22,937 shares of the biotechnology company’s stock worth $484,000 after buying an additional 677 shares during the period. Finally, Rathbone Brothers plc increased its stake in shares of Exelixis by 4.3% in the 3rd quarter. Rathbone Brothers plc now owns 19,300 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 800 shares during the last quarter. 82.80% of the stock is owned by hedge funds and other institutional investors.
EXEL stock opened at $22.77 on Friday. The business’s 50-day simple moving average is $21.70 and its 200 day simple moving average is $19.71. The company has a market cap of $7.29 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 0.71 and a beta of 0.79. Exelixis has a twelve month low of $15.50 and a twelve month high of $25.77.
Exelixis Company Profile (Get Rating)
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.